Profile data is unavailable for this security.
About the company
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
- Revenue in USD (TTM)19.87m
- Net income in USD-22.89m
- Incorporated2012
- Employees157.00
- LocationProQR Therapeutics NVZernikedreef 9LEIDEN 2333 CKNetherlandsNLD
- Phone+31 854894932
- Websitehttps://www.proqr.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Personalis Inc | 87.49m | -91.44m | 369.49m | 223.00 | -- | 2.22 | -- | 4.22 | -1.68 | -1.68 | 1.64 | 2.36 | 0.3751 | 7.18 | 6.45 | 392,327.30 | -39.20 | -28.84 | -45.99 | -34.72 | 31.41 | 28.65 | -104.52 | -96.01 | 4.44 | -- | 0.0098 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
| Voyager Therapeutics Inc | 143.77m | 9.02m | 372.46m | 162.00 | 44.52 | 1.11 | 26.81 | 2.59 | 0.1534 | 0.1534 | 2.75 | 6.16 | 0.3825 | -- | 43.56 | 887,462.90 | 2.40 | 0.6378 | 2.71 | 0.8203 | -- | -- | 6.28 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| enGene Holdings Inc | 0.00 | -123.44m | 376.72m | 33.00 | -- | 1.64 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 1.65m | -75.55m | 383.77m | 25.00 | -- | -- | -- | 233.30 | -0.0644 | -0.0644 | 0.0014 | -0.047 | 0.0581 | -- | -- | 65,800.00 | -260.06 | -381.58 | -- | -- | -- | -- | -4,479.03 | -6,479.25 | -- | -14.10 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| C4 Therapeutics Inc | 33.67m | -105.50m | 388.95m | 145.00 | -- | 1.60 | -- | 11.55 | -1.70 | -1.70 | 0.5217 | 3.44 | 0.095 | -- | 6.21 | 232,193.10 | -29.76 | -25.91 | -33.20 | -29.45 | -- | -- | -313.35 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Design Therapeutics Inc | 0.00 | -47.78m | 391.25m | 54.00 | -- | 1.55 | -- | -- | -0.8465 | -0.8465 | 0.00 | 4.46 | 0.00 | -- | -- | 0.00 | -17.02 | -- | -17.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Cartesian Therapeutics Inc | 47.94m | -244.83m | 404.52m | 38.00 | -- | 537.99 | -- | 8.44 | -37.79 | -37.79 | 3.25 | 0.0315 | 0.1708 | -- | 9.86 | 1,261,526.00 | -87.23 | -43.66 | -94.16 | -66.84 | -- | -- | -510.72 | -136.35 | -- | -0.3505 | 0.00 | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| 4D Molecular Therapeutics Inc | 20.22m | -109.89m | 409.00m | 201.00 | -- | 0.6944 | -- | 20.23 | -2.22 | -2.22 | 0.435 | 11.33 | 0.0416 | -- | -- | 137,544.20 | -22.60 | -32.67 | -23.39 | -34.90 | -- | -- | -543.51 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Akebia Therapeutics Inc | 169.88m | -45.99m | 410.06m | 167.00 | -- | -- | -- | 2.41 | -0.2207 | -0.2207 | 0.8338 | -0.2383 | 0.7684 | 1.33 | 6.20 | 1,017,240.00 | -20.80 | -37.42 | -31.00 | -56.00 | 84.79 | 69.13 | -27.07 | -82.25 | 1.21 | -2.52 | -- | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Absci Corp | 3.25m | -92.26m | 413.35m | 155.00 | -- | 1.86 | -- | 127.18 | -0.9331 | -0.9331 | 0.0327 | 1.95 | 0.0128 | -- | 2.03 | 20,967.74 | -36.20 | -- | -40.23 | -- | -- | -- | -2,838.89 | -- | -- | -129.46 | 0.0284 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| ProQR Therapeutics NV | 19.87m | -22.89m | 421.50m | 157.00 | -- | 9.61 | -- | 21.21 | -0.2813 | -0.2813 | 0.2442 | 0.4143 | 0.1406 | -- | -- | 126,569.80 | -15.98 | -35.51 | -20.63 | -40.51 | -- | -- | -113.62 | -926.31 | -- | -- | 0.3687 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Lexicon Pharmaceuticals Inc | 3.64m | -202.11m | 430.18m | 285.00 | -- | 1.79 | -- | 118.15 | -0.7783 | -0.7783 | 0.0139 | 0.6639 | 0.0106 | 0.7239 | 2.20 | 12,775.44 | -58.57 | -24.41 | -63.55 | -29.01 | 92.47 | 98.49 | -5,550.87 | -84.92 | 11.49 | -11.96 | 0.2931 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| Ginkgo Bioworks Holdings Inc | 184.34m | -897.68m | 441.11m | 1.22k | -- | 5.19 | -- | 2.39 | -18.03 | -18.03 | 3.69 | 1.62 | 0.0941 | -- | 4.20 | 151,342.40 | -45.83 | -- | -50.04 | -- | 80.22 | -- | -486.98 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| Organogenesis Holdings Inc | 448.39m | -16.54m | 457.38m | 862.00 | -- | 1.74 | -- | 1.02 | -0.125 | -0.125 | 3.38 | 1.99 | 1.00 | 4.27 | 4.49 | 520,176.30 | -3.70 | 5.46 | -4.51 | 6.90 | 75.14 | 74.94 | -3.69 | 4.81 | 2.42 | 8.33 | 0.2001 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Grail Inc | 109.74m | -2.88bn | 468.53m | 1.37k | -- | 0.1738 | -- | 4.27 | -99.94 | -99.94 | 3.91 | 86.80 | -- | -- | -- | 81,894.77 | -- | -47.45 | -- | -48.55 | 44.06 | -- | -2,627.35 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
| GH Research PLC | -100.00bn | -100.00bn | 476.06m | 49.00 | -- | 2.40 | -- | -- | -- | -- | -- | 3.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -- | -- | -58.47 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to ProQR Therapeutics NV's reporting currency: US Dollar USD
20.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Privium Fund Management BVas of 30 Sep 2024 | 5.63m | 6.90% |
| Adage Capital Management LPas of 30 Jun 2024 | 3.63m | 4.44% |
| EcoR1 Capital, LLCas of 30 Jun 2024 | 2.04m | 2.50% |
| M28 Capital Management LPas of 30 Jun 2024 | 1.02m | 1.25% |
| DAFNA Capital Management LLCas of 30 Jun 2024 | 905.58k | 1.11% |
| Ghost Tree Capital LLCas of 30 Jun 2024 | 900.00k | 1.10% |
| De Grote Voskuil Capital BVas of 31 Dec 2023 | 800.00k | 0.98% |
| Macquarie Investment Management Business Trustas of 30 Jun 2024 | 620.00k | 0.76% |
| Ikarian Capital LLCas of 30 Jun 2024 | 483.58k | 0.59% |
| DWS Investments (UK) Ltd.as of 30 Jun 2024 | 385.15k | 0.47% |
More ▼
Data from 31 Dec 2023 - 30 Sep 2024Source: FactSet Research Systems Inc.
